



Labcorp Selects Medidata’s Sensor Cloud to Expand Decentralized Clinical Trial Capabilities, Enabling First-in-Kind Industry Partnership for Digital Biomarker Discovery

The Agreement Introduces a New Collaboration Model to Advance the Use of Medical-Grade Sensors and Accelerate Biomarker Discovery

New York, NY -- Sep. 13, 2021 -- Medidata, a Dassault Systèmes company, and [Labcorp Drug Development](#), a global company providing clinical laboratory and end-to-end drug development services, today announced they have entered into an agreement using the [Medidata Sensor Cloud](#). Medidata will receive and process medical-grade sensor data within drug, vaccine and device trials across Labcorp Drug Development’s clinical trial portfolio, enhancing their decentralized clinical trial (DCT) offerings.

Sensor Cloud is a transformative platform for managing a broad range of sensor and digital health technology data and establishing interoperability with other clinical data sources. Launched earlier this year, Sensor Cloud integrates seamlessly with the [Medidata Clinical Cloud](#) and supports remote, continuous patient data collection from both Medidata and third-party, medical-grade sensors. This innovation provides a more comprehensive view of the patient experience through cutting-edge data ingestion, data standardization across all sensor types, and deep analytical capabilities that will ultimately lead to new digital biomarker discovery and digital endpoint deployment.

“Sensor Cloud solves key technical, operational, and analytical challenges that have historically stifled the widespread usage of medical devices in clinical research,” said Ben Schlatka, vice president of digital biomarker solutions at Medidata. “This technology is urgently needed, with device usage dramatically escalating as patients, sponsors and sites demand greater flexibility during clinical trials. Combining the power of Sensor Cloud with Labcorp’s innovative approach to clinical research and its scale in clinical diagnostics will transform how patient data are collected, managed, analyzed and leveraged—driving faster, more effective drug development and overall better health outcomes.”

In addition, Labcorp and Medidata will use Sensor Cloud to co-develop digital biomarkers across a broad array of medical devices and therapeutic areas. The goal of this first-of-its-kind collaboration is to build a library of digital biomarkers that can be used to advance therapeutic research and create new, digital diagnostics. The first project will be an at-home version of the

[Six Minute Walk Test](#) (6MWT), which is widely used in clinics to measure functional capacity in patients with heart failure, pulmonary conditions, physical function disorders and rare diseases.

“High-quality, medical-grade sensors offer the potential to understand patient disease processes with objective digital precision in a real-world setting, replacing subjective assessments that have limited clinical value,” said Bill Hanlon, PhD, president of Clinical Therapeutic and Regulatory Sciences at Labcorp Drug Development. “Labcorp’s collaboration with Medidata is poised to advance sensor and digital biomarker usage in clinical research in an unprecedented fashion, and will make clinical research and care processes more patient-centric, risk-based, efficient, personalized, and informative.”

Digital biomarkers are often defined as objective, quantifiable physiological and behavioral data collected and measured by digital devices such as portable, wearable, implantable, or ingestible sensors. The data collected are typically used to explain, influence and/or predict health-related outcomes. But, before the data can be truly useful to researchers, patients and clinicians, it must be captured, standardized and interoperable. In this way, Sensor Cloud’s capabilities make it a foundational tool for sensor usage in clinical research and development.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,700+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us [@Medidata](#).

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and

IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Contact

Thomas Paoella
Senior Director, Corporate Communications & Affairs
+1-848-203-7596
tpaoella@medidata.com

Paul Oestreicher
External Communications Director
+1-917-522-4692
poestreicher@medidata.com